These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 34450264)

  • 1. Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways.
    Vieira SRL; Schapira AHV
    Free Radic Biol Med; 2021 Nov; 175():42-55. PubMed ID: 34450264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocerebrosidase and Parkinson disease: Recent advances.
    Schapira AH
    Mol Cell Neurosci; 2015 May; 66(Pt A):37-42. PubMed ID: 25802027
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Smith L; Schapira AHV
    Cells; 2022 Apr; 11(8):. PubMed ID: 35455941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
    Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
    Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between glucocerebrosidase mutations and Parkinson disease.
    Migdalska-Richards A; Schapira AH
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
    Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
    Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.
    Behl T; Kaur G; Fratila O; Buhas C; Judea-Pusta CT; Negrut N; Bustea C; Bungau S
    Transl Neurodegener; 2021 Jan; 10(1):4. PubMed ID: 33446243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications.
    Balestrino R; Schapira AHV
    Neuroscientist; 2018 Oct; 24(5):540-559. PubMed ID: 29400127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons.
    Gegg ME; Verona G; Schapira AHV
    Hum Mol Genet; 2020 Jun; 29(10):1716-1728. PubMed ID: 32391886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations.
    Li H; Ham A; Ma TC; Kuo SH; Kanter E; Kim D; Ko HS; Quan Y; Sardi SP; Li A; Arancio O; Kang UJ; Sulzer D; Tang G
    Autophagy; 2019 Jan; 15(1):113-130. PubMed ID: 30160596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [GBA mutations and Parkinson's disease].
    Wang DX; Xie JX; Song N
    Sheng Li Xue Bao; 2018 Jun; 70(3):294-300. PubMed ID: 29926071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
    Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
    J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine.
    Blandini F; Cilia R; Cerri S; Pezzoli G; Schapira AHV; Mullin S; Lanciego JL
    Mov Disord; 2019 Jan; 34(1):9-21. PubMed ID: 30589955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies.
    Chiasserini D; Paciotti S; Eusebi P; Persichetti E; Tasegian A; Kurzawa-Akanbi M; Chinnery PF; Morris CM; Calabresi P; Parnetti L; Beccari T
    Mol Neurodegener; 2015 Mar; 10():15. PubMed ID: 25881142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A versatile fluorescence-quenched substrate for quantitative measurement of glucocerebrosidase activity within live cells.
    Deen MC; Zhu Y; Gros C; Na N; Gilormini PA; Shen DL; Bhosale S; Anastasi N; Wang R; Shan X; Harde E; Jagasia R; Lynn FC; Vocadlo DJ
    Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2200553119. PubMed ID: 35858317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.
    Gegg ME; Menozzi E; Schapira AHV
    Neurobiol Dis; 2022 May; 166():105663. PubMed ID: 35183702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
    McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
    Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.
    Yap TL; Gruschus JM; Velayati A; Westbroek W; Goldin E; Moaven N; Sidransky E; Lee JC
    J Biol Chem; 2011 Aug; 286(32):28080-8. PubMed ID: 21653695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.
    Magalhaes J; Gegg ME; Migdalska-Richards A; Doherty MK; Whitfield PD; Schapira AH
    Hum Mol Genet; 2016 Aug; 25(16):3432-3445. PubMed ID: 27378698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.